Pharmaust director Sam Wright, Dr Wayne Best, Epichem Managing Director, Prof Peter Klinken, Chief Scientist of WA and Robert Bishop, PharmAust Director at the official opening of Epichem's new chemistry laboratory in Perth.

Pharmaust opens new drug lab at Technology Park

Epichem, a wholly owned subsidiary of ASX listed biotech hopeful Pharmaust, has reached the pinnacle of its 13 year existence with the opening of its new state of the art chemistry lab in Technology Park in Bentley.

The new lab which is double the size of the old one that was previously operated on site at Murdoch University, cost $1.6m and boasts a serious brains trust of 13 PHD’s amongst its 18 staff.

Epichem, which provides hi-tech products and services in chemistry to global drug discovery and pharmaceutical industries, counts amongst its customer base some of the worlds largest multinational pharmaceutical companies.

It has also provided services to numerous Australian drug discovery companies, Universities and medical research institutes.

Epichem has a remarkable record that includes exporting medical products and services to over 33 countries around the world and they are currently part of a global consortium that is looking to find a cure for the debilitating Chagas Disease.

Epichem has specialized over time in anti-cancer, antiviral and antiparasitic  drugs and whilst they have had many successes, most of them are not announced by Epichem due to confidentiality obligations to the companies that engage them.

Epichem sets Pharmaust apart from other listed biotech hopefuls as it provides an income stream for the company whilst they work on proving up their own unique anti-cancer drug known as Monepantel.

The new Epichem lab, complete with its 13 fully funded PHD’s provides a unique opportunity for Pharmaust to lift itself above the pack of listed biotech hopefuls without the associated financial drain that would normally accompany such an investment.

Pharmaust is about to move into a phase 2 trial by introducing its ant-cancer drug Monepantel to people at the same time that they undertake chemotherapy in order to determine what effect the combination of both Monepantel and chemotherapy will have.

Epichem’s Managing Director, Dr Wayne Best, said “We are very excited at the prospect of having the extra capacity to broaden our customer base and provide new products and services."

Director of both Epichem and PharmAust, Robert Bishop, said “There is a significant Brains Trust at Epichem, including [13] PhDs, and we are convinced that Epichem has an exciting future and is now unleashed to achieve its full potential. This is great for PharmAust and, of course, for Perth”.


Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

BN30 Index

Index = 100 as of 4 Jan 2016
Source: Morningstar

Total Shareholder Return as at 30/09/16

1 year TSR5 year TSR
105thFortescue Metals Group182%5%
453rdIluka Resources4%-10%
462ndWoodside Petroleum3%3%
729thAtlas Iron-64%-67%
774 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$0 Other
$0 Other
$0 Issued
Total value as at the date of the transaction
Source: Morningstar


1st-Fortescue Metals Group$9,806.1m
3rd-Woodside Petroleum$6,935.4m
4th↑Iluka Resources$884.1m
5th↑Atlas Iron$803.7m
519 listed resources companies ranked by revenue.
Source: Morningstar

Remuneration from Fortescue Metals Group

3rdNev Power$5.992m
12thStephen Pearce$2.551m
26thNick Cernotta$1.566m
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer